Prenetics Global (NASDAQ:PRE) Trading 3.8% Higher

Prenetics Global Limited (NASDAQ:PRE) shares were up 3.8% during mid-day trading on Thursday . The stock traded as high as $5.36 and last traded at $4.97. Approximately 188,526 shares traded hands during mid-day trading, an increase of 77% from the average daily volume of 106,356 shares. The stock had previously closed at $4.79.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald dropped their target price on shares of Prenetics Global from $10.00 to $9.00 and set an “overweight” rating on the stock in a research report on Thursday, April 4th.

Prenetics Global Stock Up 3.8 %

The firm’s 50-day moving average price is $4.40 and its two-hundred day moving average price is $4.81. The firm has a market capitalization of $45.43 million, a PE ratio of -1.04 and a beta of -0.11.

Prenetics Global (NASDAQ:PRE) last released its earnings results on Monday, April 1st. The company reported ($0.52) earnings per share for the quarter. The firm had revenue of $5.43 million during the quarter. Prenetics Global had a negative return on equity of 11.15% and a negative net margin of 193.60%. Equities research analysts forecast that Prenetics Global Limited will post -3.59 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Prenetics Global stock. Nomura Holdings Inc. boosted its stake in shares of Prenetics Global Limited (NASDAQ:PRE) by 140.4% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 193,963 shares of the company’s stock after purchasing an additional 113,288 shares during the period. Nomura Holdings Inc. owned about 2.12% of Prenetics Global worth $1,146,000 at the end of the most recent reporting period. 25.01% of the stock is owned by hedge funds and other institutional investors.

Prenetics Global Company Profile

Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies.